The ASCO Daily News spoke recently with Edward S. Kim, MD, of the Carolinas Healthcare System Levine Cancer Institute, about key data presented during the 2018 ASCO Annual Meeting regarding drug activity across tumor types.
Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in patients with metastatic squamous non–small cell lung cancer (NSCLC)
On June 4, Gregory H. Reaman, MD, FASCO, professor of pediatrics at George Washington University School of Medicine and Health Sciences, will receive the Pediatric Oncology Award for his outstanding leadership and achievements in the field.
ASCO’s Partners in Progress Award, to be presented June 4, honors an individual whose patient advocacy has impacted public awareness about cancer or resulted in additional support—either legislatively or fiscally—for cancer research, treatment, prevention, or care.
Patients with relapsed or refractory multiple myeloma treated with once-weekly carfilzomib had a higher response rate than patients treated with the twice-weekly regimen in the ARROW study, introducing the potential for more convenient dosing for patients.
Analyzing cell-free DNA (cfDNA) circulating in plasma or serum can help oncologists determine the genotype of tumors noninvasively to guide treatment decisions and may eventually allow them to monitor treatment response, predict recurrence, and screen for cancer.